ID   EPHB2_HUMAN             Reviewed;        1055 AA.
AC   P29323; O43477; Q5T0U6; Q5T0U7; Q5T0U8;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 5.
DT   10-MAY-2017, entry version 209.
DE   RecName: Full=Ephrin type-B receptor 2;
DE            EC=2.7.10.1;
DE   AltName: Full=Developmentally-regulated Eph-related tyrosine kinase;
DE   AltName: Full=ELK-related tyrosine kinase;
DE   AltName: Full=EPH tyrosine kinase 3;
DE   AltName: Full=EPH-like kinase 5;
DE            Short=EK5;
DE            Short=hEK5;
DE   AltName: Full=Renal carcinoma antigen NY-REN-47;
DE   AltName: Full=Tyrosine-protein kinase TYRO5;
DE   AltName: Full=Tyrosine-protein kinase receptor EPH-3;
DE   Flags: Precursor;
GN   Name=EPHB2; Synonyms=DRT, EPHT3, EPTH3, ERK, HEK5, TYRO5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8033077;
RA   Kiyokawa E., Takai S., Tanaka M., Iwase T., Suzuki M., Xiang Y.Y.,
RA   Naito Y., Yamada K., Sugimura H., Kino I.;
RT   "Overexpression of ERK, an EPH family receptor protein tyrosine
RT   kinase, in various human tumors.";
RL   Cancer Res. 54:3645-3650(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Fetal brain;
RX   PubMed=8589679; DOI=10.1093/hmg/4.11.2033;
RA   Ikegaki N., Tang X.X., Liu X.-G., Biegel J.A., Allen C., Yoshioka A.,
RA   Sulman E.P., Brodeur G.M., Pleasure D.E.;
RT   "Molecular characterization and chromosomal localization of DRT
RT   (EPHT3): a developmentally regulated human protein-tyrosine kinase
RT   gene of the EPH family.";
RL   Hum. Mol. Genet. 4:2033-2045(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=9696046; DOI=10.1038/sj.onc.1201960;
RA   Tang X.X., Pleasure D.E., Brodeur G.M., Ikegaki N.;
RT   "A variant transcript encoding an isoform of the human protein
RT   tyrosine kinase EPHB2 is generated by alternative splicing and
RT   alternative use of polyadenylation signals.";
RL   Oncogene 17:521-526(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-986 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=7898931;
RA   Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M.,
RA   Basu R., Welcher A.A.;
RT   "cDNA cloning and tissue distribution of five human EPH-like receptor
RT   protein-tyrosine kinases.";
RL   Oncogene 10:897-905(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 509-986 (ISOFORM 2).
RC   TISSUE=Fetal brain;
RX   PubMed=7601466; DOI=10.1016/0888-7543(95)80224-A;
RA   Saito T., Seki N., Matsuda Y., Kitahara M., Murata M., Kanda N.,
RA   Nomura N., Yamamoto T., Hori T.-A.;
RT   "Identification of the human ERK gene as a putative receptor tyrosine
RT   kinase and its chromosomal localization to 1p36.1: a comparative
RT   mapping of human, mouse, and rat chromosomes.";
RL   Genomics 26:382-384(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 640-986 (ISOFORM 2).
RC   TISSUE=Gastric carcinoma;
RX   PubMed=7688222; DOI=10.1006/bbrc.1993.1878;
RA   Iwase T., Tanaka M., Suzuki M., Naito Y., Sugimura H., Kino I.;
RT   "Identification of protein-tyrosine kinase genes preferentially
RT   expressed in embryo stomach and gastric cancer.";
RL   Biochem. Biophys. Res. Commun. 194:698-705(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 652-712.
RX   PubMed=1648701;
RA   Chan J., Watt V.M.;
RT   "eek and erk, new members of the eph subclass of receptor protein-
RT   tyrosine kinases.";
RL   Oncogene 6:1057-1061(1991).
RN   [9]
RP   NOMENCLATURE.
RX   PubMed=9267020;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [10]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-983 (ISOFORM 2),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-984 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 910-986 (ISOFORM SHORT).
RX   PubMed=9933164; DOI=10.1126/science.283.5403.833;
RA   Thanos C.D., Goodwill K.E., Bowie J.U.;
RT   "Oligomeric structure of the human EphB2 receptor SAM domain.";
RL   Science 283:833-836(1999).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 20-195 OF HOMODIMER IN
RP   COMPLEX WITH ANTAGONISTIC PEPTIDE, AND DISULFIDE BOND.
RX   PubMed=17897949; DOI=10.1074/jbc.M706340200;
RA   Chrencik J.E., Brooun A., Recht M.I., Nicola G., Davis L.K.,
RA   Abagyan R., Widmer H., Pasquale E.B., Kuhn P.;
RT   "Three-dimensional structure of the EphB2 receptor in complex with an
RT   antagonistic peptide reveals a novel mode of inhibition.";
RL   J. Biol. Chem. 282:36505-36513(2007).
RN   [15]
RP   VARIANTS PROSTATE CANCER HIS-199; SER-279; ASN-679 AND MET-909, AND
RP   FUNCTION AS A TUMOR SUPPRESSOR.
RX   PubMed=15300251; DOI=10.1038/ng1408;
RA   Huusko P., Ponciano-Jackson D., Wolf M., Kiefer J.A., Azorsa D.O.,
RA   Tuzmen S., Weaver D., Robbins C., Moses T., Allinen M., Hautaniemi S.,
RA   Chen Y., Elkahloun A., Basik M., Bova G.S., Bubendorf L., Lugli A.,
RA   Sauter G., Schleutker J., Ozcelik H., Elowe S., Pawson T., Trent J.M.,
RA   Carpten J.D., Kallioniemi O.-P., Mousses S.;
RT   "Nonsense-mediated decay microarray analysis identifies mutations of
RT   EPHB2 in human prostate cancer.";
RL   Nat. Genet. 36:979-983(2004).
RN   [16]
RP   VARIANTS PROSTATE CANCER SER-279; ALA-650 AND VAL-883.
RX   PubMed=16155194; DOI=10.1136/jmg.2005.035790;
RA   Kittles R.A., Baffoe-Bonnie A.B., Moses T.Y., Robbins C.M.,
RA   Ahaghotu C., Huusko P., Pettaway C., Vijayakumar S., Bennett J.,
RA   Hoke G., Mason T., Weinrich S., Trent J.M., Collins F.S., Mousses S.,
RA   Bailey-Wilson J., Furbert-Harris P., Dunston G., Powell I.J.,
RA   Carpten J.D.;
RT   "A common nonsense mutation in EphB2 is associated with prostate
RT   cancer risk in African American men with a positive family history.";
RL   J. Med. Genet. 43:507-511(2006).
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-279; GLY-289; VAL-361; ASN-678 AND
RP   TRP-844.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       transmembrane ephrin-B family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. Functions in axon guidance during development. Involved
CC       in the guidance of commissural axons, that form a major
CC       interhemispheric connection between the 2 temporal lobes of the
CC       cerebral cortex. Also involved in guidance of contralateral inner
CC       ear efferent growth cones at the midline and of retinal ganglion
CC       cell axons to the optic disk. In addition to axon guidance, also
CC       regulates dendritic spines development and maturation and
CC       stimulates the formation of excitatory synapses. Upon activation
CC       by EFNB1, abolishes the ARHGEF15-mediated negative regulation on
CC       excitatory synapse formation. Controls other aspects of
CC       development including angiogenesis, palate development and in
CC       inner ear development through regulation of endolymph production.
CC       Forward and reverse signaling through the EFNB2/EPHB2 complex
CC       regulate movement and adhesion of cells that tubularize the
CC       urethra and septate the cloaca. May function as a tumor
CC       suppressor. {ECO:0000269|PubMed:15300251}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The
CC       heterotetramer is composed of an ephrin dimer and a receptor
CC       dimer. Oligomerization is probably required to induce biological
CC       responses (By similarity). Interacts (via PDZ-binding motif) with
CC       GRIP1 and PICK1 (via PDZ domain) (By similarity). Interacts with
CC       ARHGEF15; mediates ARHGEF15 phosphorylation, ubiquitination and
CC       degradation by the proteasome. Interacts with AQP1; involved in
CC       endolymph production in the inner ear. {ECO:0000250,
CC       ECO:0000269|PubMed:17897949}.
CC   -!- INTERACTION:
CC       P49790:NUP153; NbExp=2; IntAct=EBI-1059294, EBI-286779;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cell projection, axon {ECO:0000250}. Cell projection,
CC       dendrite {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=EPHB2v, Long;
CC         IsoId=P29323-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P29323-2; Sequence=VSP_003016, VSP_003017;
CC         Note=Contains a phosphoserine at position 983.
CC         {ECO:0000244|PubMed:19369195};
CC       Name=3;
CC         IsoId=P29323-3; Sequence=VSP_015713, VSP_003016, VSP_003017;
CC         Note=No experimental confirmation available. Contains a
CC         phosphoserine at position 984. {ECO:0000244|PubMed:19369195};
CC   -!- TISSUE SPECIFICITY: Brain, heart, lung, kidney, placenta,
CC       pancreas, liver and skeletal muscle. Preferentially expressed in
CC       fetal brain.
CC   -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy
CC       originating in tissues of the prostate. Most prostate cancers are
CC       adenocarcinomas that develop in the acini of the prostatic ducts.
CC       Other rare histopathologic types of prostate cancer that occur in
CC       approximately 5% of patients include small cell carcinoma,
CC       mucinous carcinoma, prostatic ductal carcinoma, transitional cell
CC       carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid
CC       cystic carcinoma (basaloid), signet-ring cell carcinoma and
CC       neuroendocrine carcinoma. {ECO:0000269|PubMed:15300251,
CC       ECO:0000269|PubMed:16155194}. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis. EPHB2 mutations
CC       have been found in a prostate cancer cell line derived from a
CC       brain metastasis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D31661; BAA06506.1; -; mRNA.
DR   EMBL; L41939; AAA99310.1; -; mRNA.
DR   EMBL; AF025304; AAB94602.1; -; mRNA.
DR   EMBL; AL035704; CAI22645.1; -; Genomic_DNA.
DR   EMBL; AL158086; CAI22645.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22645.1; JOINED; Genomic_DNA.
DR   EMBL; AL035704; CAI22646.1; -; Genomic_DNA.
DR   EMBL; AL158086; CAI22646.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22646.1; JOINED; Genomic_DNA.
DR   EMBL; AL035704; CAI22647.2; -; Genomic_DNA.
DR   EMBL; AL158086; CAI22647.2; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22647.2; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI22897.1; -; Genomic_DNA.
DR   EMBL; AL035704; CAI22897.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22897.1; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI22898.1; -; Genomic_DNA.
DR   EMBL; AL512444; CAI22898.1; JOINED; Genomic_DNA.
DR   EMBL; AL035704; CAI22898.1; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI22899.2; -; Genomic_DNA.
DR   EMBL; AL035704; CAI22899.2; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI22899.2; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI16428.1; -; Genomic_DNA.
DR   EMBL; AL035704; CAI16428.1; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI16428.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI16429.1; -; Genomic_DNA.
DR   EMBL; AL035704; CAI16429.1; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI16429.1; JOINED; Genomic_DNA.
DR   EMBL; AL512444; CAI16430.2; -; Genomic_DNA.
DR   EMBL; AL035704; CAI16430.2; JOINED; Genomic_DNA.
DR   EMBL; AL158086; CAI16430.2; JOINED; Genomic_DNA.
DR   EMBL; L36643; AAA74244.1; -; mRNA.
DR   EMBL; D37827; BAA07073.1; -; mRNA.
DR   EMBL; D14717; BAA03537.1; -; mRNA.
DR   EMBL; X59292; CAA41981.1; -; Genomic_DNA.
DR   CCDS; CCDS229.2; -. [P29323-2]
DR   CCDS; CCDS230.1; -. [P29323-3]
DR   CCDS; CCDS81279.1; -. [P29323-1]
DR   PIR; A57174; A57174.
DR   PIR; I78842; I78842.
DR   RefSeq; NP_001296122.1; NM_001309193.1. [P29323-1]
DR   RefSeq; NP_004433.2; NM_004442.7. [P29323-3]
DR   RefSeq; NP_059145.2; NM_017449.4. [P29323-2]
DR   UniGene; Hs.380705; -.
DR   UniGene; Hs.523329; -.
DR   PDB; 1B4F; X-ray; 1.95 A; A/B/C/D/E/F/G/H=908-985.
DR   PDB; 1F0M; X-ray; 2.20 A; A=908-985.
DR   PDB; 2QBX; X-ray; 2.30 A; A/B=20-196.
DR   PDB; 3ZFM; X-ray; 2.27 A; A=604-898.
DR   PDBsum; 1B4F; -.
DR   PDBsum; 1F0M; -.
DR   PDBsum; 2QBX; -.
DR   PDBsum; 3ZFM; -.
DR   ProteinModelPortal; P29323; -.
DR   SMR; P29323; -.
DR   BioGrid; 108362; 18.
DR   DIP; DIP-1162N; -.
DR   IntAct; P29323; 4.
DR   MINT; MINT-5005955; -.
DR   STRING; 9606.ENSP00000363763; -.
DR   BindingDB; P29323; -.
DR   ChEMBL; CHEMBL3290; -.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   GuidetoPHARMACOLOGY; 1831; -.
DR   iPTMnet; P29323; -.
DR   PhosphoSitePlus; P29323; -.
DR   SwissPalm; P29323; -.
DR   BioMuta; EPHB2; -.
DR   DMDM; 76803654; -.
DR   EPD; P29323; -.
DR   MaxQB; P29323; -.
DR   PaxDb; P29323; -.
DR   PeptideAtlas; P29323; -.
DR   PRIDE; P29323; -.
DR   DNASU; 2048; -.
DR   Ensembl; ENST00000374630; ENSP00000363761; ENSG00000133216. [P29323-2]
DR   Ensembl; ENST00000374632; ENSP00000363763; ENSG00000133216. [P29323-3]
DR   Ensembl; ENST00000400191; ENSP00000383053; ENSG00000133216. [P29323-1]
DR   GeneID; 2048; -.
DR   KEGG; hsa:2048; -.
DR   UCSC; uc001bge.4; human. [P29323-1]
DR   CTD; 2048; -.
DR   DisGeNET; 2048; -.
DR   GeneCards; EPHB2; -.
DR   H-InvDB; HIX0028518; -.
DR   HGNC; HGNC:3393; EPHB2.
DR   HPA; CAB013647; -.
DR   HPA; HPA071200; -.
DR   MalaCards; EPHB2; -.
DR   MIM; 176807; phenotype.
DR   MIM; 600997; gene.
DR   MIM; 603688; phenotype.
DR   neXtProt; NX_P29323; -.
DR   OpenTargets; ENSG00000133216; -.
DR   Orphanet; 1331; Familial prostate cancer.
DR   PharmGKB; PA27825; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118975; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P29323; -.
DR   KO; K05111; -.
DR   OMA; VNNLDKM; -.
DR   OrthoDB; EOG091G00W0; -.
DR   PhylomeDB; P29323; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-373760; L1CAM interactions.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P29323; -.
DR   SIGNOR; P29323; -.
DR   ChiTaRS; EPHB2; human.
DR   EvolutionaryTrace; P29323; -.
DR   GeneWiki; EPH_receptor_B2; -.
DR   GenomeRNAi; 2048; -.
DR   PRO; PR:P29323; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000133216; -.
DR   CleanEx; HS_EPHB2; -.
DR   ExpressionAtlas; P29323; baseline and differential.
DR   Genevisible; P29323; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IEA:Ensembl.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; ISS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0007413; P:axonal fasciculation; ISS:UniProtKB.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; IEA:Ensembl.
DR   GO; GO:0071679; P:commissural neuron axon guidance; ISS:UniProtKB.
DR   GO; GO:0022038; P:corpus callosum development; ISS:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; TAS:UniProtKB.
DR   GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; ISS:UniProtKB.
DR   GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB.
DR   GO; GO:0050878; P:regulation of body fluid levels; ISS:UniProtKB.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl.
DR   GO; GO:0099557; P:trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmission; IEA:Ensembl.
DR   GO; GO:0001655; P:urogenital system development; ISS:UniProtKB.
DR   CDD; cd10477; EphR_LBD_B2; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034238; EphB2_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Cell projection; Complete proteome; Developmental protein;
KW   Disease mutation; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Neurogenesis; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tumor suppressor;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19   1055       Ephrin type-B receptor 2.
FT                                /FTId=PRO_0000016827.
FT   TOPO_DOM     19    543       Extracellular. {ECO:0000255}.
FT   TRANSMEM    544    564       Helical. {ECO:0000255}.
FT   TOPO_DOM    565   1055       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       20    202       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      324    434       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      435    530       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      621    884       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      913    977       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     627    635       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       984    986       PDZ-binding (in isoform 2).
FT                                {ECO:0000255}.
FT   COMPBIAS    184    324       Cys-rich.
FT   ACT_SITE    746    746       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     653    653       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     602    602       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P54753}.
FT   CARBOHYD    265    265       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    336    336       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    428    428       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    482    482       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     62    184       {ECO:0000269|PubMed:17897949}.
FT   DISULFID     97    107       {ECO:0000269|PubMed:17897949}.
FT   VAR_SEQ     568    568       R -> RR (in isoform 3).
FT                                {ECO:0000303|PubMed:8589679}.
FT                                /FTId=VSP_015713.
FT   VAR_SEQ     986    986       G -> V (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:7601466,
FT                                ECO:0000303|PubMed:7688222,
FT                                ECO:0000303|PubMed:7898931,
FT                                ECO:0000303|PubMed:8033077,
FT                                ECO:0000303|PubMed:8589679}.
FT                                /FTId=VSP_003016.
FT   VAR_SEQ     987   1055       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:7601466,
FT                                ECO:0000303|PubMed:7688222,
FT                                ECO:0000303|PubMed:7898931,
FT                                ECO:0000303|PubMed:8033077,
FT                                ECO:0000303|PubMed:8589679}.
FT                                /FTId=VSP_003017.
FT   VARIANT     199    199       R -> H (in prostate cancer;
FT                                dbSNP:rs201754821).
FT                                {ECO:0000269|PubMed:15300251}.
FT                                /FTId=VAR_032853.
FT   VARIANT     279    279       A -> S (in prostate cancer;
FT                                dbSNP:rs35882952).
FT                                {ECO:0000269|PubMed:15300251,
FT                                ECO:0000269|PubMed:16155194,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032854.
FT   VARIANT     289    289       C -> G. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042172.
FT   VARIANT     361    361       I -> V (in dbSNP:rs56180036).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042173.
FT   VARIANT     650    650       V -> A (in prostate cancer;
FT                                dbSNP:rs142173175).
FT                                {ECO:0000269|PubMed:16155194}.
FT                                /FTId=VAR_032855.
FT   VARIANT     678    678       D -> N (in dbSNP:rs28936395).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042174.
FT   VARIANT     679    679       H -> N (in prostate cancer).
FT                                {ECO:0000269|PubMed:15300251}.
FT                                /FTId=VAR_032856.
FT   VARIANT     844    844       R -> W (in dbSNP:rs55826626).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042175.
FT   VARIANT     883    883       M -> V (in prostate cancer;
FT                                dbSNP:rs372653137).
FT                                {ECO:0000269|PubMed:16155194}.
FT                                /FTId=VAR_032857.
FT   VARIANT     909    909       I -> M (in prostate cancer).
FT                                {ECO:0000269|PubMed:15300251}.
FT                                /FTId=VAR_032858.
FT   CONFLICT      1     20       MALRRLGAALLLLPLLAAVE -> MWVPVLALPVCTYA
FT                                (in Ref. 1; BAA06506). {ECO:0000305}.
FT   CONFLICT    154    154       G -> D (in Ref. 1; BAA06506).
FT                                {ECO:0000305}.
FT   CONFLICT    476    476       K -> KQ (in Ref. 1; BAA06506).
FT                                {ECO:0000305}.
FT   CONFLICT    495    496       Missing (in Ref. 5; AAA74244).
FT                                {ECO:0000305}.
FT   CONFLICT    532    532       E -> D (in Ref. 1; BAA06506).
FT                                {ECO:0000305}.
FT   CONFLICT    589    589       M -> I (in Ref. 5; AAA74244).
FT                                {ECO:0000305}.
FT   CONFLICT    671    671       A -> R (in Ref. 7; BAA03537).
FT                                {ECO:0000305}.
FT   CONFLICT    788    788       I -> F (in Ref. 5; AAA74244).
FT                                {ECO:0000305}.
FT   CONFLICT    853    853       S -> A (in Ref. 1; BAA06506, 6; BAA07073
FT                                and 7; BAA03537). {ECO:0000305}.
FT   CONFLICT    923    923       E -> K (in Ref. 1; BAA06506, 6; BAA07073
FT                                and 7; BAA03537). {ECO:0000305}.
FT   CONFLICT    958    958       V -> L (in Ref. 2; AAA99310).
FT                                {ECO:0000305}.
FT   STRAND       21     25       {ECO:0000244|PDB:2QBX}.
FT   HELIX        26     28       {ECO:0000244|PDB:2QBX}.
FT   STRAND       36     39       {ECO:0000244|PDB:2QBX}.
FT   STRAND       44     49       {ECO:0000244|PDB:2QBX}.
FT   STRAND       55     61       {ECO:0000244|PDB:2QBX}.
FT   STRAND       66     68       {ECO:0000244|PDB:2QBX}.
FT   STRAND       71     74       {ECO:0000244|PDB:2QBX}.
FT   STRAND       84     94       {ECO:0000244|PDB:2QBX}.
FT   HELIX        97     99       {ECO:0000244|PDB:2QBX}.
FT   STRAND      111    120       {ECO:0000244|PDB:2QBX}.
FT   STRAND      130    132       {ECO:0000244|PDB:2QBX}.
FT   STRAND      135    141       {ECO:0000244|PDB:2QBX}.
FT   STRAND      148    152       {ECO:0000244|PDB:2QBX}.
FT   STRAND      155    166       {ECO:0000244|PDB:2QBX}.
FT   STRAND      171    183       {ECO:0000244|PDB:2QBX}.
FT   STRAND      185    194       {ECO:0000244|PDB:2QBX}.
FT   HELIX       618    620       {ECO:0000244|PDB:3ZFM}.
FT   STRAND      621    626       {ECO:0000244|PDB:3ZFM}.
FT   STRAND      635    640       {ECO:0000244|PDB:3ZFM}.
FT   STRAND      648    655       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       661    674       {ECO:0000244|PDB:3ZFM}.
FT   STRAND      685    689       {ECO:0000244|PDB:3ZFM}.
FT   STRAND      691    700       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       707    712       {ECO:0000244|PDB:3ZFM}.
FT   TURN        713    716       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       720    739       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       749    751       {ECO:0000244|PDB:3ZFM}.
FT   STRAND      752    754       {ECO:0000244|PDB:3ZFM}.
FT   STRAND      760    762       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       790    792       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       795    800       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       805    820       {ECO:0000244|PDB:3ZFM}.
FT   TURN        826    829       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       832    840       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       853    862       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       873    885       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       887    890       {ECO:0000244|PDB:3ZFM}.
FT   HELIX       918    924       {ECO:0000244|PDB:1B4F}.
FT   HELIX       928    930       {ECO:0000244|PDB:1B4F}.
FT   HELIX       931    936       {ECO:0000244|PDB:1B4F}.
FT   HELIX       942    945       {ECO:0000244|PDB:1B4F}.
FT   HELIX       950    955       {ECO:0000244|PDB:1B4F}.
FT   HELIX       961    982       {ECO:0000244|PDB:1B4F}.
SQ   SEQUENCE   1055 AA;  117493 MW;  4F8BFEDC45986483 CRC64;
     MALRRLGAAL LLLPLLAAVE ETLMDSTTAT AELGWMVHPP SGWEEVSGYD ENMNTIRTYQ
     VCNVFESSQN NWLRTKFIRR RGAHRIHVEM KFSVRDCSSI PSVPGSCKET FNLYYYEADF
     DSATKTFPNW MENPWVKVDT IAADESFSQV DLGGRVMKIN TEVRSFGPVS RSGFYLAFQD
     YGGCMSLIAV RVFYRKCPRI IQNGAIFQET LSGAESTSLV AARGSCIANA EEVDVPIKLY
     CNGDGEWLVP IGRCMCKAGF EAVENGTVCR GCPSGTFKAN QGDEACTHCP INSRTTSEGA
     TNCVCRNGYY RADLDPLDMP CTTIPSAPQA VISSVNETSL MLEWTPPRDS GGREDLVYNI
     ICKSCGSGRG ACTRCGDNVQ YAPRQLGLTE PRIYISDLLA HTQYTFEIQA VNGVTDQSPF
     SPQFASVNIT TNQAAPSAVS IMHQVSRTVD SITLSWSQPD QPNGVILDYE LQYYEKELSE
     YNATAIKSPT NTVTVQGLKA GAIYVFQVRA RTVAGYGRYS GKMYFQTMTE AEYQTSIQEK
     LPLIIGSSAA GLVFLIAVVV IAIVCNRRGF ERADSEYTDK LQHYTSGHMT PGMKIYIDPF
     TYEDPNEAVR EFAKEIDISC VKIEQVIGAG EFGEVCSGHL KLPGKREIFV AIKTLKSGYT
     EKQRRDFLSE ASIMGQFDHP NVIHLEGVVT KSTPVMIITE FMENGSLDSF LRQNDGQFTV
     IQLVGMLRGI AAGMKYLADM NYVHRDLAAR NILVNSNLVC KVSDFGLSRF LEDDTSDPTY
     TSALGGKIPI RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM TNQDVINAIE
     QDYRLPPPMD CPSALHQLML DCWQKDRNHR PKFGQIVNTL DKMIRNPNSL KAMAPLSSGI
     NLPLLDRTIP DYTSFNTVDE WLEAIKMGQY KESFANAGFT SFDVVSQMMM EDILRVGVTL
     AGHQKKILNS IQVMRAQMNQ IQSVEGQPLA RRPRATGRTK RCQPRDVTKK TCNSNDGKKK
     GMGKKKTDPG RGREIQGIFF KEDSHKESND CSCGG
//
